Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTI-103
- Development stage
- Preclinical
- Lead developer
- Postsurgical Therapeutics
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Local
01
Overview
PTI-103 is a preclinical-stage drug delivery system developed by Postsurgical Therapeutics for the local, postsurgical targeted therapy of cancer. It utilizes a proprietary poly(lactic-co-glycolic acid) (PLGA) platform, which can be formulated as either microspheres or an in-situ gel. The system is designed for implantation or local delivery at the site of tumor resection to provide sustained release of anticancer agents, aiming to eliminate residual cancer cells and prevent local recurrence. As of the latest reports, PTI-103 has completed non-GLP efficacy animal testing.
Beyond the preview
Go deeper on PTI-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTI-103.